“Emerging research has suggested several neurobiological behavioral similarities between substance use disorders and excessive eating,” Grilo said.
The behavioral treatment program started with behavioral weight-loss therapy, and then integrated the oral anorexiant sibutramine, and CBT. Sibutramine (Meridia) was withdrawn from the U.S. market in 2010 by its maker, Abbott Laboratories, under pressure from the FDA, which cited concerns over the drug’s minimal efficacy coupled with increased risk of adverse cardiovascular events.
Wikipedia: Sibutramine is a centrally-acting serotonin-norepinephrine reuptake inhibitor structurally related to amphetamines, although its mechanism of action is distinct… It was sold under a variety of brand names including Reductil, Meridia, Siredia, and Sibutrex. It is classified as a Schedule IV controlled substance in the United States.
Binge Eating: Stepping Stone to Drug Use?
The prospective study looked at associations between over- and binge eating with overweight, obesity, binge drinking, depression, and drug and marijuana use risks in a population of 14,166 participants, ages 9 to 15, at baseline (mean age 12).
At baseline and in select time periods, the authors found the following among the participants:
- Obese or overweight: 22.3% in 1996 and 30.7% between 1996 and 2007
- Frequent binge drinking: 4.3% in 1996 and 60% between 1999 and 2007
- Used marijuana: 12.2% in 1996 and 40.7% between 2001 and 2007
- Used a drug other than marijuana: 9.1% in 1996 and 31.9% between 2001 and 2007